Trial Outcomes & Findings for Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis (NCT NCT00936065)

Last Updated: 2012-04-09

Results Overview

Combined assessment of lesion severity and area affected into single score; range: 0 (no disease) to 72 (maximal disease). Body was divided into 4 sections (head, arms, trunk, legs); each area scored by itself and scores combined for final PASI. For each section, area of skin involved was estimated: 0 (0%) to 6 (90 - 100%), and severity estimated by clinical signs: erythema, induration, and desquamation; scale: 0 (none) to 4 (exceptionally striking). Final PASI = sum of severity parameters for each section \* area score \* weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4).

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

60 participants

Primary outcome timeframe

Week 24

Results posted on

2012-04-09

Participant Flow

Participant milestones

Participant milestones
Measure	Etanercept Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin Acitretin 10 mg subcutaneous injection BID for 24 weeks
Overall Study STARTED	21	20	19
Overall Study Received Treatment	21	20	18
Overall Study Study Assessments Performed	21	19	18
Overall Study COMPLETED	17	16	12
Overall Study NOT COMPLETED	4	4	7

Reasons for withdrawal

Reasons for withdrawal
Measure	Etanercept Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin Acitretin 10 mg subcutaneous injection BID for 24 weeks
Overall Study Adverse Event	1	0	1
Overall Study Lack of Efficacy	1	0	1
Overall Study Lost to Follow-up	1	0	0
Overall Study Protocol Violation	1	2	1
Overall Study Withdrawal by Subject	0	2	4

Baseline Characteristics

Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks	Total n=58 Participants Total of all reporting groups
Age Continuous	38.57 years STANDARD_DEVIATION 9.53 • n=5 Participants	35.5 years STANDARD_DEVIATION 8.75 • n=7 Participants	42.39 years STANDARD_DEVIATION 11.95 • n=5 Participants	38.78 years STANDARD_DEVIATION 10.31 • n=4 Participants
Sex: Female, Male Female	5 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	10 Participants n=4 Participants
Sex: Female, Male Male	16 Participants n=5 Participants	17 Participants n=7 Participants	15 Participants n=5 Participants	48 Participants n=4 Participants

PRIMARY outcome

Timeframe: Week 24

Population: Modified intent to treat (mITT) population: randomized participants who took at least 1 dose of test article and had both baseline and on-therapy PASI evaluations; Last Observation Carried Forward (LOCF)

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Percentage of Participants Achieving a 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 24	52.38 percentage of participants Interval 29.78 to 74.29	57.89 percentage of participants Interval 33.5 to 79.75	22.22 percentage of participants Interval 6.41 to 47.64

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, 12, 18, and 24

Population: mITT; LOCF

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 2	4.76 percentage of participants Interval 0.12 to 23.82	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 8	71.43 percentage of participants Interval 47.82 to 88.72	57.89 percentage of participants Interval 33.5 to 79.75	27.78 percentage of participants Interval 9.69 to 53.48
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 12	76.19 percentage of participants Interval 52.83 to 91.78	78.95 percentage of participants Interval 54.43 to 93.95	22.22 percentage of participants Interval 6.41 to 47.64
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 18	76.19 percentage of participants Interval 52.83 to 91.78	84.21 percentage of participants Interval 60.42 to 96.62	38.89 percentage of participants Interval 17.3 to 64.25
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 24	71.43 percentage of participants Interval 47.82 to 88.72	84.21 percentage of participants Interval 60.42 to 96.62	44.44 percentage of participants Interval 21.53 to 69.24
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 4	47.62 percentage of participants Interval 25.71 to 70.22	15.79 percentage of participants Interval 3.38 to 39.58	11.11 percentage of participants Interval 1.38 to 34.71

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

PGA of Psoriasis: score based on dermatologist's assessment of disease averaged over all lesions of head, scalp, and neck. Overall lesions were graded for induration, erythema, and scaling; range: 0 (no evidence) to 5 (severe). The sum of the 3 scores was divided by 3 to obtain a final PGA score. Higher scores indicate greater severity of disease. Assessment of clear = PGA score of 0 (no evidence).

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Baseline	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Week 4	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Week 18	9.52 Percentage of participants Interval 1.17 to 30.38	5.26 Percentage of participants Interval 0.13 to 26.03	5.56 Percentage of participants Interval 0.14 to 27.29
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Week 24	9.52 Percentage of participants Interval 1.17 to 30.38	10.53 Percentage of participants Interval 1.3 to 33.14	5.56 Percentage of participants Interval 0.14 to 27.29
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Week 2	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Week 8	4.76 Percentage of participants Interval 0.12 to 23.82	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0
Percentage of Participants Achieving a Status on the Physician Global Assessment (PGA) of Psoriasis of Clear Week 12	9.52 Percentage of participants Interval 1.17 to 30.38	0 Percentage of participants Interval 0.0 to 0.0	0 Percentage of participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Baseline	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Week 2	0 percentage of participants Interval 0.0 to 0.0	0 percentage of participants Interval 0.0 to 0.0	5.56 percentage of participants Interval 0.14 to 27.29
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Week 4	19.05 percentage of participants Interval 5.45 to 41.91	5.26 percentage of participants Interval 0.13 to 26.03	11.11 percentage of participants Interval 1.38 to 34.71
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Week 8	28.57 percentage of participants Interval 11.28 to 52.18	21.05 percentage of participants Interval 6.05 to 45.57	5.56 percentage of participants Interval 0.14 to 27.29
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Week 12	42.86 percentage of participants Interval 21.82 to 65.98	21.05 percentage of participants Interval 6.05 to 45.57	5.56 percentage of participants Interval 0.14 to 27.29
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Week 18	33.33 percentage of participants Interval 14.59 to 56.97	31.58 percentage of participants Interval 12.58 to 56.55	16.67 percentage of participants Interval 3.58 to 41.42
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear Week 24	52.38 percentage of participants Interval 29.78 to 74.29	52.63 percentage of participants Interval 28.86 to 75.55	16.67 percentage of participants Interval 3.58 to 41.42

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Baseline	14.29 percentage of participants Interval 3.05 to 36.34	5.26 percentage of participants Interval 0.13 to 26.03	16.67 percentage of participants Interval 3.58 to 41.42
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Week 2	33.33 percentage of participants Interval 14.59 to 56.97	26.32 percentage of participants Interval 9.15 to 51.2	11.11 percentage of participants Interval 1.38 to 34.71
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Week 4	42.86 percentage of participants Interval 21.82 to 65.98	47.37 percentage of participants Interval 24.45 to 74.14	16.67 percentage of participants Interval 3.58 to 41.42
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Week 8	61.90 percentage of participants Interval 38.44 to 81.89	42.11 percentage of participants Interval 20.25 to 66.5	27.78 percentage of participants Interval 9.69 to 53.48
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Week 12	76.19 percentage of participants Interval 52.83 to 91.78	78.95 percentage of participants Interval 54.43 to 93.95	33.33 percentage of participants Interval 13.34 to 59.01
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Week 18	80.95 percentage of participants Interval 58.09 to 94.55	84.21 percentage of participants Interval 60.42 to 96.62	38.89 percentage of participants Interval 17.3 to 64.25
Percentage of Participants Achieving a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild Week 24	76.19 percentage of participants Interval 52.83 to 91.78	84.21 percentage of participants Interval 60.42 to 96.62	33.33 percentage of participants Interval 13.34 to 59.01

SECONDARY outcome

Timeframe: Baseline up to Week 24

Population: mITT

PASI 50 defined as a 50% or greater improvement in PASI score from Baseline

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Time to Achieve a PASI 50 Score	56 days Interval 28.0 to 56.0	56 days Interval 54.0 to 84.0	126 days Interval 56.0 to Not Available (NA): The number of events to observe the upper limit of 95% Confidence Interval (CI) did not occur during the specified period.

SECONDARY outcome

Timeframe: Baseline up to Week 24

Population: mITT

PASI 75 defined as a 75% or greater improvement in PASI score from Baseline

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Time to Achieve a PASI 75 Score	126 days Interval 56.0 to 146.0	146 days Interval 124.0 to The number of events to observe the upper limit of 95% CI did not occur during the specified period.	NA days Interval 127.0 to The number of events to observe the median time to PASI 75 did not occur during the specified period.

SECONDARY outcome

Timeframe: Baseline up to Week 24

Population: mITT

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Time to Achieve a Status on the PGA of Psoriasis of Clear or Almost Clear or Mild	57 days Interval 19.0 to 84.0	57 days Interval 14.0 to 84.0	169 days Interval 56.0 to The number of events to observe the upper limit of 95% CI did not occur during the specified period.

SECONDARY outcome

Timeframe: Baseline up to Week 24

Population: mITT

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Time to Achieve a Status on the PGA of Psoriasis of Clear or Almost Clear	167 days Interval 55.0 to 172.0	165 days Interval 59.0 to The number of events to observe the upper limit of 95% CI did not occur during the specified period.	NA days Interval 87.0 to The number of events to observe the median time to achieve PGA of Clear or Almost Clear did not occur during the specified period.

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18, and 24

Population: mITT; LOCF

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in the PGA of Psoriasis Change at Week 8	-1.34 units on a scale Standard Deviation 1.07	-1.09 units on a scale Standard Deviation 0.86	-0.43 units on a scale Standard Deviation 0.91
Change From Baseline in the PGA of Psoriasis Change at Week 12	-1.62 units on a scale Standard Deviation 1.33	-1.42 units on a scale Standard Deviation 0.69	-0.48 units on a scale Standard Deviation 0.98
Change From Baseline in the PGA of Psoriasis Baseline	3.40 units on a scale Standard Deviation 0.82	3.38 units on a scale Standard Deviation 0.59	3.50 units on a scale Standard Deviation 0.92
Change From Baseline in the PGA of Psoriasis Change at Week 2	-0.51 units on a scale Standard Deviation 0.71	-0.35 units on a scale Standard Deviation 0.58	0.02 units on a scale Standard Deviation 0.56
Change From Baseline in the PGA of Psoriasis Change at Week 4	-1.00 units on a scale Standard Deviation 1.03	-0.84 units on a scale Standard Deviation 0.60	-0.26 units on a scale Standard Deviation 0.74
Change From Baseline in the PGA of Psoriasis Change at Week 18	-1.58 units on a scale Standard Deviation 1.33	-1.68 units on a scale Standard Deviation 1.00	-0.69 units on a scale Standard Deviation 1.35
Change From Baseline in the PGA of Psoriasis Change at Week 24	-1.67 units on a scale Standard Deviation 1.47	-1.86 units on a scale Standard Deviation 1.06	-0.71 units on a scale Standard Deviation 1.37

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Combined assessment of lesion severity, area affected into single score; range:0(no disease) to 72(maximal disease).Body divided into 4 sections (head, arms, trunk, legs); each area scored by itself and scores combined for final PASI. For each section, area of skin involved was estimated:0(0%) to 6(90-100%), severity estimated by clinical signs: erythema, induration, desquamation; scale: 0(none) to 4(maximum). Final PASI = sum of severity parameters for each section \* area score \* weight of section(head:0.1,arm:0.2,body: 0.3, leg:0.4). Change=Week X-Baseline, smaller scores show improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in the PASI Score Change at Week 24	-12.16 units on a scale Standard Deviation 12.15	-13.92 units on a scale Standard Deviation 5.75	-9.62 units on a scale Standard Deviation 10.10
Change From Baseline in the PASI Score Baseline	20.83 units on a scale Standard Deviation 14.02	19.75 units on a scale Standard Deviation 9.85	26.31 units on a scale Standard Deviation 13.63
Change From Baseline in the PASI Score Change at Week 2	-5.38 units on a scale Standard Deviation 7.13	-3.27 units on a scale Standard Deviation 1.88	-3.17 units on a scale Standard Deviation 5.60
Change From Baseline in the PASI Score Change at Week 4	-9.98 units on a scale Standard Deviation 10.64	-6.45 units on a scale Standard Deviation 3.19	-4.06 units on a scale Standard Deviation 5.68
Change From Baseline in the PASI Score Change at Week 8	-11.11 units on a scale Standard Deviation 10.89	-9.96 units on a scale Standard Deviation 3.73	-6.84 units on a scale Standard Deviation 9.57
Change From Baseline in the PASI Score Change at Week 12	-11.97 units on a scale Standard Deviation 11.63	-11.39 units on a scale Standard Deviation 4.72	-6.71 units on a scale Standard Deviation 6.81
Change From Baseline in the PASI Score Change at Week 18	-12.13 units on a scale Standard Deviation 11.67	-13.54 units on a scale Standard Deviation 6.80	-8.77 units on a scale Standard Deviation 8.54

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Change from Baseline in the percentage of the surface area of the body affected by psoriasis. Change = Week x minus Baseline, where smaller scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Baseline	32.98 percentage of BSA Standard Deviation 20.21	32.50 percentage of BSA Standard Deviation 24.15	39.75 percentage of BSA Standard Deviation 22.96
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	-2.64 percentage of BSA Standard Deviation 6.69	-1.55 percentage of BSA Standard Deviation 5.07	-0.36 percentage of BSA Standard Deviation 5.54
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	-12.67 percentage of BSA Standard Deviation 13.17	-7.97 percentage of BSA Standard Deviation 9.27	-5.14 percentage of BSA Standard Deviation 16.96
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	-15.43 percentage of BSA Standard Deviation 14.90	-10.29 percentage of BSA Standard Deviation 9.19	-5.08 percentage of BSA Standard Deviation 11.89
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	-16.57 percentage of BSA Standard Deviation 14.70	-14.76 percentage of BSA Standard Deviation 11.61	-9.25 percentage of BSA Standard Deviation 16.72
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	-7.36 percentage of BSA Standard Deviation 10.89	-4.50 percentage of BSA Standard Deviation 6.48	-0.75 percentage of BSA Standard Deviation 7.66
Change From Baseline in Percent Body Surface Area (BSA) Involvement of Psoriasis at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	-17.52 percentage of BSA Standard Deviation 14.91	-16.87 percentage of BSA Standard Deviation 10.79	-10.30 percentage of BSA Standard Deviation 18.86

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF; Number of participants analyzed (N)= participants with evaluable data

Participants were asked to rate the severity of their joint pain on a 6-point scale, where 0=good and 5=severe. Change = Week X minus Baseline, where smaller scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=18 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Baseline	0.67 units on a scale Standard Deviation 1.43	0.56 units on a scale Standard Deviation 1.15	0.94 units on a scale Standard Deviation 1.73
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 4	0.29 units on a scale Standard Deviation 1.19	-0.06 units on a scale Standard Deviation 0.42	-0.72 units on a scale Standard Deviation 1.81
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 8	0.19 units on a scale Standard Deviation 0.81	-0.22 units on a scale Standard Deviation 0.88	-0.56 units on a scale Standard Deviation 1.72
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 12	0.00 units on a scale Standard Deviation 0.63	-0.28 units on a scale Standard Deviation 0.96	-0.44 units on a scale Standard Deviation 2.36
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 18	-0.05 units on a scale Standard Deviation 0.67	-0.28 units on a scale Standard Deviation 1.02	-0.44 units on a scale Standard Deviation 1.85
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 2	0.00 units on a scale Standard Deviation 0.71	0.00 units on a scale Standard Deviation 0.49	-0.44 units on a scale Standard Deviation 1.10
Change From Baseline in Subject Global Assessment (SGA) of Joint Pain at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 24	0.29 units on a scale Standard Deviation 1.06	-0.39 units on a scale Standard Deviation 0.85	-0.61 units on a scale Standard Deviation 2.03

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12 ,18 and 24

Population: mITT; LOCF; Number of participants analyzed (N)= participants with evaluable data

Participants were asked to rate the severity of their psoriasis disease activity on a 6-point scale, where 0=good and 5=severe. Change = Week X minus Baseline, where smaller scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=18 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 12	-2.67 units on a scale Standard Deviation 1.56	-2.28 units on a scale Standard Deviation 1.53	-1.61 units on a scale Standard Deviation 1.72
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 18	-2.57 units on a scale Standard Deviation 1.99	-2.11 units on a scale Standard Deviation 1.78	-1.83 units on a scale Standard Deviation 1.76
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Baseline	3.90 units on a scale Standard Deviation 1.09	3.94 units on a scale Standard Deviation 1.06	4.72 units on a scale Standard Deviation 0.67
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 2	-0.90 units on a scale Standard Deviation 1.58	-0.33 units on a scale Standard Deviation 1.24	-0.72 units on a scale Standard Deviation 1.02
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 4	-1.86 units on a scale Standard Deviation 1.28	-0.94 units on a scale Standard Deviation 1.26	-0.83 units on a scale Standard Deviation 1.04
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 8	-2.29 units on a scale Standard Deviation 1.79	-1.89 units on a scale Standard Deviation 1.49	-1.67 units on a scale Standard Deviation 1.71
Change From Baseline in SGA of Psoriasis at Weeks 2, 4, 8, 12 ,18 and 24 Change at Week 24	-1.81 units on a scale Standard Deviation 2.20	-2.39 units on a scale Standard Deviation 1.54	-1.72 units on a scale Standard Deviation 1.93

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12 ,18 and 24

Population: mITT; LOCF; Number of participants analyzed (N)= participants with evaluable data

Participants were asked to rate the severity of their psoriasis itching on a 6-point scale, where 0=good and 5=severe. Change = Week X minus Baseline, where smaller scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=18 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in SGA of Itching at Each Visit Change at Week 4	-1.52 units on a scale Standard Deviation 1.33	-0.61 units on a scale Standard Deviation 1.65	-0.39 units on a scale Standard Deviation 2.03
Change From Baseline in SGA of Itching at Each Visit Change at Week 8	-1.86 units on a scale Standard Deviation 2.06	-1.06 units on a scale Standard Deviation 1.76	-1.28 units on a scale Standard Deviation 1.71
Change From Baseline in SGA of Itching at Each Visit Change at Week 12	-2.10 units on a scale Standard Deviation 2.07	-1.44 units on a scale Standard Deviation 2.09	-1.22 units on a scale Standard Deviation 1.73
Change From Baseline in SGA of Itching at Each Visit Baseline	3.33 units on a scale Standard Deviation 1.35	3.11 units on a scale Standard Deviation 1.81	3.72 units on a scale Standard Deviation 1.45
Change From Baseline in SGA of Itching at Each Visit Change at Week 2	-0.67 units on a scale Standard Deviation 1.59	0.28 units on a scale Standard Deviation 1.74	-0.39 units on a scale Standard Deviation 1.29
Change From Baseline in SGA of Itching at Each Visit Change at Week 18	-1.81 units on a scale Standard Deviation 2.06	-1.83 units on a scale Standard Deviation 1.76	-1.17 units on a scale Standard Deviation 1.62
Change From Baseline in SGA of Itching at Each Visit Change at Week 24	-1.19 units on a scale Standard Deviation 2.23	-1.83 units on a scale Standard Deviation 2.04	-1.06 units on a scale Standard Deviation 1.89

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the overall appearance of their skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.81 Units on a scale Standard Deviation 1.25	0.79 Units on a scale Standard Deviation 1.40	0.28 Units on a scale Standard Deviation 1.41
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.57 Units on a scale Standard Deviation 1.16	0.95 Units on a scale Standard Deviation 1.31	0.50 Units on a scale Standard Deviation 1.38
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	2.10 Units on a scale Standard Deviation 1.58	1.58 Units on a scale Standard Deviation 1.71	0.78 Units on a scale Standard Deviation 1.40
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	2.10 Units on a scale Standard Deviation 1.58	1.74 Units on a scale Standard Deviation 1.76	0.56 Units on a scale Standard Deviation 1.38
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	2.24 Units on a scale Standard Deviation 1.87	1.95 Units on a scale Standard Deviation 1.54	1.06 Units on a scale Standard Deviation 1.66
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.76 Units on a scale Standard Deviation 1.67	2.05 Units on a scale Standard Deviation 1.18	1.11 Units on a scale Standard Deviation 1.84
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 1, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	0.67 Units on a scale Standard Deviation 0.80	0.74 Units on a scale Standard Deviation 0.99	0.44 Units on a scale Standard Deviation 0.78

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on the flaking of their skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	1.00 Units on a scale Standard Deviation 1.30	0.84 Units on a scale Standard Deviation 1.21	0.56 Units on a scale Standard Deviation 0.78
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	1.14 Units on a scale Standard Deviation 1.53	1.21 Units on a scale Standard Deviation 1.51	0.39 Units on a scale Standard Deviation 1.50
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.57 Units on a scale Standard Deviation 1.36	0.68 Units on a scale Standard Deviation 1.42	0.94 Units on a scale Standard Deviation 1.66
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	2.38 Units on a scale Standard Deviation 1.83	1.53 Units on a scale Standard Deviation 1.95	1.11 Units on a scale Standard Deviation 1.78
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	2.67 Units on a scale Standard Deviation 1.88	1.63 Units on a scale Standard Deviation 1.46	0.83 Units on a scale Standard Deviation 1.76
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	2.33 Units on a scale Standard Deviation 2.01	1.89 Units on a scale Standard Deviation 1.41	1.28 Units on a scale Standard Deviation 1.84
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 2, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.90 Units on a scale Standard Deviation 2.17	2.21 Units on a scale Standard Deviation 1.18	1.17 Units on a scale Standard Deviation 1.86

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on the redness of their skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	2.00 Units on a scale Standard Deviation 2.02	2.21 Units on a scale Standard Deviation 1.23	1.00 Units on a scale Standard Deviation 1.41
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	0.90 Units on a scale Standard Deviation 1.18	0.63 Units on a scale Standard Deviation 1.01	0.72 Units on a scale Standard Deviation 0.89
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.86 Units on a scale Standard Deviation 1.20	1.32 Units on a scale Standard Deviation 1.34	0.17 Units on a scale Standard Deviation 1.20
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	0.95 Units on a scale Standard Deviation 1.24	1.16 Units on a scale Standard Deviation 1.17	0.44 Units on a scale Standard Deviation 1.04
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	2.05 Units on a scale Standard Deviation 2.04	1.58 Units on a scale Standard Deviation 1.71	0.83 Units on a scale Standard Deviation 1.34
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	2.19 Units on a scale Standard Deviation 1.97	1.68 Units on a scale Standard Deviation 1.67	0.61 Units on a scale Standard Deviation 1.38
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 3, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	2.05 Units on a scale Standard Deviation 2.20	2.16 Units on a scale Standard Deviation 1.21	1.22 Units on a scale Standard Deviation 1.52

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on tightness in the skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	2.43 Units on a scale Standard Deviation 2.34	1.32 Units on a scale Standard Deviation 1.29	0.83 Units on a scale Standard Deviation 1.76
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	2.67 Units on a scale Standard Deviation 2.18	1.74 Units on a scale Standard Deviation 1.48	0.61 Units on a scale Standard Deviation 2.20
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.90 Units on a scale Standard Deviation 2.47	2.00 Units on a scale Standard Deviation 1.05	0.56 Units on a scale Standard Deviation 1.62
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	1.33 Units on a scale Standard Deviation 1.28	1.11 Units on a scale Standard Deviation 1.05	1.83 Units on a scale Standard Deviation 1.76
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	1.48 Units on a scale Standard Deviation 1.50	0.42 Units on a scale Standard Deviation 1.61	-0.11 Units on a scale Standard Deviation 1.57
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	2.19 Units on a scale Standard Deviation 1.72	0.79 Units on a scale Standard Deviation 1.13	0.44 Units on a scale Standard Deviation 1.79
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 4, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	2.48 Units on a scale Standard Deviation 2.16	2.05 Units on a scale Standard Deviation 1.18	0.78 Units on a scale Standard Deviation 1.77

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on bleeding of the skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.57 Units on a scale Standard Deviation 1.60	0.68 Units on a scale Standard Deviation 1.53	0.28 Units on a scale Standard Deviation 1.74
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.00 Units on a scale Standard Deviation 1.95	0.74 Units on a scale Standard Deviation 1.45	0.56 Units on a scale Standard Deviation 2.09
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.43 Units on a scale Standard Deviation 1.99	1.05 Units on a scale Standard Deviation 1.22	0.44 Units on a scale Standard Deviation 1.82
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.81 Units on a scale Standard Deviation 1.86	2.84 Units on a scale Standard Deviation 1.64	2.89 Units on a scale Standard Deviation 2.14
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.00 Units on a scale Standard Deviation 2.32	0.84 Units on a scale Standard Deviation 1.64	0.61 Units on a scale Standard Deviation 2.20
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.43 Units on a scale Standard Deviation 2.23	0.74 Units on a scale Standard Deviation 1.28	0.78 Units on a scale Standard Deviation 2.41
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 5, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.38 Units on a scale Standard Deviation 2.25	1.16 Units on a scale Standard Deviation 1.92	0.67 Units on a scale Standard Deviation 2.09

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on burning sensation of the skin. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.81 Units on a scale Standard Deviation 1.69	2.37 Units on a scale Standard Deviation 1.86	2.28 Units on a scale Standard Deviation 2.05
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.57 Units on a scale Standard Deviation 1.57	0.37 Units on a scale Standard Deviation 1.30	-0.44 Units on a scale Standard Deviation 1.65
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	0.76 Units on a scale Standard Deviation 1.81	0.89 Units on a scale Standard Deviation 1.49	-0.06 Units on a scale Standard Deviation 2.53
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.24 Units on a scale Standard Deviation 1.92	1.58 Units on a scale Standard Deviation 1.71	0.61 Units on a scale Standard Deviation 2.33
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	0.86 Units on a scale Standard Deviation 1.98	1.37 Units on a scale Standard Deviation 1.54	0.78 Units on a scale Standard Deviation 1.90
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.14 Units on a scale Standard Deviation 1.96	1.16 Units on a scale Standard Deviation 1.86	0.56 Units on a scale Standard Deviation 2.28
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 6, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	0.67 Units on a scale Standard Deviation 2.35	1.05 Units on a scale Standard Deviation 1.72	0.44 Units on a scale Standard Deviation 2.06

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on skin pain. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.95 Units on a scale Standard Deviation 1.63	2.21 Units on a scale Standard Deviation 1.78	2.72 Units on a scale Standard Deviation 2.11
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	0.90 Units on a scale Standard Deviation 1.76	1.00 Units on a scale Standard Deviation 1.41	0.50 Units on a scale Standard Deviation 2.26
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.24 Units on a scale Standard Deviation 2.00	1.32 Units on a scale Standard Deviation 1.45	0.89 Units on a scale Standard Deviation 2.30
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.29 Units on a scale Standard Deviation 2.05	1.32 Units on a scale Standard Deviation 1.45	0.78 Units on a scale Standard Deviation 2.73
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.10 Units on a scale Standard Deviation 2.02	1.63 Units on a scale Standard Deviation 1.71	1.00 Units on a scale Standard Deviation 2.45
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.48 Units on a scale Standard Deviation 1.75	0.89 Units on a scale Standard Deviation 1.59	0.28 Units on a scale Standard Deviation 1.96
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 7, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	0.62 Units on a scale Standard Deviation 2.27	1.37 Units on a scale Standard Deviation 1.89	0.67 Units on a scale Standard Deviation 2.14

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on joint pain. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	4.43 Units on a scale Standard Deviation 1.16	3.79 Units on a scale Standard Deviation 1.40	4.17 Units on a scale Standard Deviation 1.58
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	-0.52 Units on a scale Standard Deviation 1.21	0.05 Units on a scale Standard Deviation 0.91	0.22 Units on a scale Standard Deviation 1.77
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	-0.33 Units on a scale Standard Deviation 1.20	0.21 Units on a scale Standard Deviation 1.03	0.33 Units on a scale Standard Deviation 1.53
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	-0.33 Units on a scale Standard Deviation 1.11	-0.05 Units on a scale Standard Deviation 1.18	0.17 Units on a scale Standard Deviation 0.99
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	-0.29 Units on a scale Standard Deviation 1.15	0.21 Units on a scale Standard Deviation 1.18	0.00 Units on a scale Standard Deviation 2.35
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	-0.14 Units on a scale Standard Deviation 0.85	0.37 Units on a scale Standard Deviation 1.38	-0.28 Units on a scale Standard Deviation 1.60
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 8, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	-0.57 Units on a scale Standard Deviation 1.47	0.05 Units on a scale Standard Deviation 1.22	0.17 Units on a scale Standard Deviation 1.95

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their comfort level with their personal appearance. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	1.14 Units on a scale Standard Deviation 1.56	0.79 Units on a scale Standard Deviation 0.79	0.83 Units on a scale Standard Deviation 1.10
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.43 Units on a scale Standard Deviation 1.21	0.63 Units on a scale Standard Deviation 1.46	-0.11 Units on a scale Standard Deviation 1.23
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.57 Units on a scale Standard Deviation 2.29	2.21 Units on a scale Standard Deviation 1.13	0.78 Units on a scale Standard Deviation 1.44
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	0.90 Units on a scale Standard Deviation 1.64	1.05 Units on a scale Standard Deviation 1.43	-0.11 Units on a scale Standard Deviation 1.23
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.48 Units on a scale Standard Deviation 1.91	1.58 Units on a scale Standard Deviation 1.61	0.44 Units on a scale Standard Deviation 1.29
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.52 Units on a scale Standard Deviation 2.18	1.89 Units on a scale Standard Deviation 1.41	0.17 Units on a scale Standard Deviation 1.34
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 9, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.90 Units on a scale Standard Deviation 2.51	1.68 Units on a scale Standard Deviation 1.29	0.72 Units on a scale Standard Deviation 1.45

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their anxiety. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.29 Units on a scale Standard Deviation 1.87	1.89 Units on a scale Standard Deviation 1.73	2.22 Units on a scale Standard Deviation 1.80
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	1.05 Units on a scale Standard Deviation 1.66	0.63 Units on a scale Standard Deviation 1.89	-0.39 Units on a scale Standard Deviation 1.54
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.24 Units on a scale Standard Deviation 1.55	1.21 Units on a scale Standard Deviation 1.84	-0.61 Units on a scale Standard Deviation 1.61
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.57 Units on a scale Standard Deviation 1.91	1.47 Units on a scale Standard Deviation 1.95	0.33 Units on a scale Standard Deviation 2.06
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.52 Units on a scale Standard Deviation 2.14	1.68 Units on a scale Standard Deviation 1.73	0.22 Units on a scale Standard Deviation 2.60
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.57 Units on a scale Standard Deviation 2.01	1.53 Units on a scale Standard Deviation 1.87	0.56 Units on a scale Standard Deviation 2.15
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 10, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.24 Units on a scale Standard Deviation 1.95	1.58 Units on a scale Standard Deviation 1.68	0.67 Units on a scale Standard Deviation 2.25

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their depression. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.43 Units on a scale Standard Deviation 1.91	1.95 Units on a scale Standard Deviation 1.72	2.33 Units on a scale Standard Deviation 1.85
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.95 Units on a scale Standard Deviation 1.32	1.11 Units on a scale Standard Deviation 1.63	-0.11 Units on a scale Standard Deviation 1.18
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.33 Units on a scale Standard Deviation 1.59	1.26 Units on a scale Standard Deviation 1.97	-0.22 Units on a scale Standard Deviation 1.59
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.19 Units on a scale Standard Deviation 2.02	1.68 Units on a scale Standard Deviation 1.70	0.67 Units on a scale Standard Deviation 1.50
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.38 Units on a scale Standard Deviation 1.83	1.47 Units on a scale Standard Deviation 2.20	0.28 Units on a scale Standard Deviation 1.41
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.71 Units on a scale Standard Deviation 2.05	1.58 Units on a scale Standard Deviation 1.64	0.17 Units on a scale Standard Deviation 2.04
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 11, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.57 Units on a scale Standard Deviation 2.09	1.47 Units on a scale Standard Deviation 1.81	0.61 Units on a scale Standard Deviation 1.58

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on their fatigue. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.95 Units on a scale Standard Deviation 1.75	1.74 Units on a scale Standard Deviation 1.52	2.78 Units on a scale Standard Deviation 1.73
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.48 Units on a scale Standard Deviation 1.86	0.89 Units on a scale Standard Deviation 1.56	-0.72 Units on a scale Standard Deviation 1.99
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	0.29 Units on a scale Standard Deviation 1.82	0.95 Units on a scale Standard Deviation 2.07	-0.33 Units on a scale Standard Deviation 2.35
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	0.48 Units on a scale Standard Deviation 1.89	1.37 Units on a scale Standard Deviation 1.61	-0.61 Units on a scale Standard Deviation 2.06
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	0.29 Units on a scale Standard Deviation 1.76	0.68 Units on a scale Standard Deviation 1.80	-0.56 Units on a scale Standard Deviation 2.01
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	0.48 Units on a scale Standard Deviation 1.89	0.95 Units on a scale Standard Deviation 1.72	-0.89 Units on a scale Standard Deviation 2.42
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 12, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	0.24 Units on a scale Standard Deviation 2.02	1.21 Units on a scale Standard Deviation 2.20	-0.67 Units on a scale Standard Deviation 2.06

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on how others responded to their personal appearance at work/school. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	2.29 Units on a scale Standard Deviation 1.85	1.53 Units on a scale Standard Deviation 1.02	1.83 Units on a scale Standard Deviation 1.62
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.00 Units on a scale Standard Deviation 1.67	0.53 Units on a scale Standard Deviation 1.50	-0.39 Units on a scale Standard Deviation 1.58
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.00 Units on a scale Standard Deviation 1.73	1.11 Units on a scale Standard Deviation 1.56	-0.22 Units on a scale Standard Deviation 1.77
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	0.95 Units on a scale Standard Deviation 1.91	1.53 Units on a scale Standard Deviation 1.43	-0.33 Units on a scale Standard Deviation 1.88
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	0.95 Units on a scale Standard Deviation 1.86	1.42 Units on a scale Standard Deviation 1.57	0.11 Units on a scale Standard Deviation 2.14
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	0.95 Units on a scale Standard Deviation 1.99	1.63 Units on a scale Standard Deviation 1.46	-0.11 Units on a scale Standard Deviation 2.05
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 13, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.05 Units on a scale Standard Deviation 1.69	0.74 Units on a scale Standard Deviation 1.05	-0.33 Units on a scale Standard Deviation 1.91

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with the treatment's effect on how their skin affected social and leisure activities. Responses were based on a 5-point scale: Very dissatisfied (0), Dissatisfied (1), Neither satisfied nor dissatisfied (2), Satisfied (3), Very satisfied (4), Never had this problem (5). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.57 Units on a scale Standard Deviation 1.36	0.74 Units on a scale Standard Deviation 1.41	-0.06 Units on a scale Standard Deviation 1.43
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.10 Units on a scale Standard Deviation 1.64	0.89 Units on a scale Standard Deviation 0.99	0.22 Units on a scale Standard Deviation 1.73
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.76 Units on a scale Standard Deviation 1.79	1.58 Units on a scale Standard Deviation 1.61	0.28 Units on a scale Standard Deviation 1.45
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.90 Units on a scale Standard Deviation 1.84	1.68 Units on a scale Standard Deviation 1.70	0.50 Units on a scale Standard Deviation 1.82
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	0.95 Units on a scale Standard Deviation 1.02	0.89 Units on a scale Standard Deviation 0.94	1.39 Units on a scale Standard Deviation 1.50
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	2.10 Units on a scale Standard Deviation 2.02	1.89 Units on a scale Standard Deviation 1.52	-0.06 Units on a scale Standard Deviation 1.70
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 14, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.57 Units on a scale Standard Deviation 2.09	1.95 Units on a scale Standard Deviation 1.61	0.28 Units on a scale Standard Deviation 2.08

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to rate, based on their experience during the past week, how satisfied or dissatisfied they were with their psoriasis therapy in general. Responses were based on a 5-point scale: very dissatisfied (0), dissatisfied (1), neither satisfied nor dissatisfied (2), satisfied (3), very satisfied (4). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	1.19 Units on a scale Standard Deviation 1.12	1.37 Units on a scale Standard Deviation 1.21	1.41 Units on a scale Standard Deviation 1.18
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	1.24 Units on a scale Standard Deviation 1.18	1.00 Units on a scale Standard Deviation 1.60	0.18 Units on a scale Standard Deviation 1.55
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	1.67 Units on a scale Standard Deviation 1.20	1.00 Units on a scale Standard Deviation 1.37	0.12 Units on a scale Standard Deviation 1.58
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	1.67 Units on a scale Standard Deviation 1.32	1.37 Units on a scale Standard Deviation 1.83	0.53 Units on a scale Standard Deviation 1.55
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	1.90 Units on a scale Standard Deviation 1.51	1.53 Units on a scale Standard Deviation 1.74	0.35 Units on a scale Standard Deviation 1.87
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	1.86 Units on a scale Standard Deviation 1.56	1.74 Units on a scale Standard Deviation 1.52	0.82 Units on a scale Standard Deviation 1.78
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 15, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	1.38 Units on a scale Standard Deviation 1.47	1.68 Units on a scale Standard Deviation 1.60	0.76 Units on a scale Standard Deviation 1.95

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to respond to the statement "I would like to continue with my current psoriasis treatment". Responses were based on a 5-point scale: strongly disagree (0), disagree(1), neither agree nor disagree (2), agree (3), strongly agree (4). Change = Week X minus Baseline, where larger scores indicate improvement.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	3.10 Units on a scale Standard Deviation 1.22	3.42 Units on a scale Standard Deviation 1.02	2.82 Units on a scale Standard Deviation 1.42
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 2	0.48 Units on a scale Standard Deviation 1.17	0.11 Units on a scale Standard Deviation 1.20	0.00 Units on a scale Standard Deviation 1.80
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 18	0.48 Units on a scale Standard Deviation 1.50	0.21 Units on a scale Standard Deviation 1.13	-0.29 Units on a scale Standard Deviation 2.08
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 4	0.67 Units on a scale Standard Deviation 1.24	0.05 Units on a scale Standard Deviation 1.18	-0.12 Units on a scale Standard Deviation 1.93
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 8	0.52 Units on a scale Standard Deviation 1.54	0.26 Units on a scale Standard Deviation 1.05	0.06 Units on a scale Standard Deviation 1.98
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 12	0.48 Units on a scale Standard Deviation 1.50	0.16 Units on a scale Standard Deviation 1.21	-0.29 Units on a scale Standard Deviation 2.14
Change From Baseline in Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 16, at Weeks 2, 4, 8, 12, 18 and 24 Change at Week 24	0.14 Units on a scale Standard Deviation 1.53	0.11 Units on a scale Standard Deviation 1.10	-0.18 Units on a scale Standard Deviation 1.88

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to answer the following question with either a "yes" or "no", "Taking into account your psoriasis symptoms, the appearance of your skin and all other problems which psoriasis causes, do you consider that your current health state is satisfactory?" Percentage of participants who responded "yes" reported.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	9.52 Percentage of participants Interval 1.17 to 30.38	15.79 Percentage of participants Interval 3.38 to 39.58	22.22 Percentage of participants Interval 6.41 to 47.64
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Week 4	42.86 Percentage of participants Interval 21.82 to 65.98	52.63 Percentage of participants Interval 28.86 to 75.55	33.33 Percentage of participants Interval 13.34 to 59.01
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Week 8	57.14 Percentage of participants Interval 34.02 to 78.18	57.89 Percentage of participants Interval 33.5 to 79.75	33.33 Percentage of participants Interval 13.34 to 59.01
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Week 12	71.43 Percentage of participants Interval 47.82 to 88.72	57.89 Percentage of participants Interval 33.5 to 79.75	33.33 Percentage of participants Interval 13.34 to 59.01
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Week 18	71.43 Percentage of participants Interval 47.82 to 88.72	63.16 Percentage of participants Interval 38.36 to 83.71	38.89 Percentage of participants Interval 17.3 to 64.25
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Week 24	57.14 Percentage of participants Interval 34.02 to 78.18	73.68 Percentage of participants Interval 48.8 to 90.85	38.89 Percentage of participants Interval 17.3 to 64.25
Change From Baseline in the Percentage of Participants Who Responded "Yes" to the Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 17, at Weeks 2, 4, 8, 12, 18 and 24 Week 2	14.29 Percentage of participants Interval 3.05 to 36.34	42.11 Percentage of participants Interval 20.25 to 66.5	27.78 Percentage of participants Interval 9.69 to 53.48

SECONDARY outcome

Timeframe: Baseline, Weeks 2, 4, 8, 12, 18 and 24

Population: mITT; LOCF

Participants completed a satisfaction survey at baseline and throughout the study. Participants were asked to answer the following question with either a "yes" or "no", "Taking into account your psoriasis symptoms, the appearance of your skin, medicine side effects and medicine ease/difficulty of use, do you consider that your current psoriasis treatment is satisfactory?" Percentage of participants who responded "yes" reported.

Outcome measures

Outcome measures
Measure	Etanercept n=21 Participants Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=19 Participants Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 Participants Acitretin 10 mg subcutaneous injection BID for 24 weeks
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Week 2	80.95 percentage of participants Interval 58.09 to 94.55	78.95 percentage of participants Interval 54.43 to 93.95	50.00 percentage of participants Interval 26.02 to 73.98
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Week 4	85.71 percentage of participants Interval 63.66 to 96.95	94.74 percentage of participants Interval 73.97 to 99.87	55.56 percentage of participants Interval 30.76 to 78.47
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Week 8	90.48 percentage of participants Interval 69.62 to 98.83	89.47 percentage of participants Interval 66.86 to 98.7	66.67 percentage of participants Interval 40.99 to 86.66
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Week 12	95.24 percentage of participants Interval 76.18 to 99.88	73.68 percentage of participants Interval 48.8 to 90.85	61.11 percentage of participants Interval 35.75 to 82.7
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Week 18	90.48 percentage of participants Interval 69.62 to 98.83	94.74 percentage of participants Interval 73.97 to 99.87	61.11 percentage of participants Interval 35.75 to 82.7
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Week 24	80.95 percentage of participants Interval 58.09 to 94.55	94.74 percentage of participants Interval 73.97 to 99.87	55.56 percentage of participants Interval 30.76 to 78.47
Change From Baseline in the Percentage of Participants Who Responded "Yes" to Psoriasis Subject Satisfaction Questionnaire (PSSQ) Question 18, at Weeks 2, 4, 8, 12, 18 and 24 Baseline	38.10 percentage of participants Interval 18.11 to 61.56	42.11 percentage of participants Interval 20.25 to 66.5	33.33 percentage of participants Interval 14.21 to 61.67

Adverse Events

Etanercept

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Etanercept and Acitretin

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Acitretin

Serious events: 1 serious events

Other events: 10 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Etanercept n=21 participants at risk Etanercept 50 milligram (mg) subcutaneous injection twice weekly (BIW) for 12 weeks followed by Etanercept 25 mg BIW for 12 weeks	Etanercept and Acitretin n=20 participants at risk Etanercept 25 mg subcutaneous injection BIW and acitretin 10 mg twice per day (BID) for 24 weeks.	Acitretin n=18 participants at risk Acitretin 10 mg subcutaneous injection BID for 24 weeks
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/21 The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.	0.00% 0/20 The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.	5.6% 1/18 The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.

Other adverse events

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER